Atezolizumab: uses, dosing, side effects & brands

How atezolizumab is dosed

From the FDA label for Tecentriq (application BLA761034). Other atezolizumab products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

Administer TECENTRIQ intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. NSCLC In the adjuvant setting, administer TECENTRIQ following resection and up to 4 cycles of platinum-based chemotherapy as 840 mg every 2 weeks, 1200 mg every 3 weeks or 1680 mg every 4 weeks for up to 1 year. ( 2.2 ) In the metastatic setting, administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. ( 2.2 ) When administering with chemotherapy with or without bevacizumab, administer TECENTRIQ prior to chemotherapy and bevacizumab when given on the same day. ( 2.2 ) Small Cell Lung Cancer Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. Administer TECENTRIQ prior to chemotherapy when given on the same day. ( 2.2 ) Hepatocellular Carcinoma Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. Administer TECENTRIQ prior to bevacizumab when given on the same day. Bevacizumab is administered at 15 mg/kg every 3 weeks. ( 2.2 ) Melanoma Following completion of a 28-day cycle of cobimetinib and vemurafenib, administer TECENTRIQ 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks with cobimetinib 60 mg orally once daily (21 days on /7 days off) and vemurafenib 720 mg orally twice daily. ( 2.2 )…

Atezolizumab side effects

Who shouldn’t take atezolizumab

Combination products containing atezolizumab

A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.

• Tecentriq Hybreza

Atezolizumab and breastfeeding

From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.

No information is available on the clinical use of atezolizumab during breastfeeding. Because atezolizumab is a large protein molecule with a molecular weight of 145,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant. Until more data become available, atezolizumab should be used with caution or avoided during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during atezolizumab therapy and for at least 5 months after the last dose.

National Institute of Child Health and Human Development, record revised April 15, 2023. LactMed states its information is not a substitute for professional judgement.

What people report to the FDA about atezolizumab

The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 21,161 reports naming atezolizumab, and the FDA flagged 97% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:

• diarrhoea1,249 reports
• pyrexia1,119 reports
• anaemia1,089 reports
• fatigue1,035 reports
• nausea794 reports
• pneumonia790 reports
• hypothyroidism767 reports
• pneumonitis764 reports

Source: openFDA drug/event (FAERS), retrieved July 25, 2026.

Related calculators